Iran slams new US sanctions, says they mean 'end of diplomacy'

New Delhi, May 28: Twitter CEO Jack Dorsey today reinforced his stance on pointing out "incorrect or disputed information about elections globally", a day after US President Donald Trump threatened to shutter social media over Twitter's actions on his posts.

Mr Dorsey appealed to "leave our employees out of this" as the face-off with Mr Trump is likely to escalate.

"Fact check: there is someone ultimately accountable for our actions as a company, and that's me. Please leave our employees out of this. We'll continue to point out incorrect or disputed information about elections globally. And we will admit to and own any mistakes we make," Mr Dorsey tweeted.

"This does not make us an 'arbiter of truth.' Our intention is to connect the dots of conflicting statements and show the information in dispute so people can judge for themselves. More transparency from us is critical so folks can clearly see the why behind our actions," said the Twitter CEO.

Fact check: there is someone ultimately accountable for our actions as a company, and that's me. Please leave our employees out of this. We'll continue to point out incorrect or disputed information about elections globally. And we will admit to and own any mistakes we make.

— jack (@jack) May 28, 2020

"Per our Civic Integrity policy (https://help.twitter.com/en/rules-and-policies/election-integrity-policy), the tweets yesterday may mislead people into thinking they don't need to register to get a ballot (only registered voters receive ballots). We're updating the link on

@realDonaldTrump tweet to make this more clear," Mr Dorsey tweeted.

Twitter had tagged two of Mr Trump's tweets in which he claimed that more mail-in voting would lead to what he called a "rigged election" this November. There is no evidence that attempts are being made to rig the election, and under the tweets Twitter posted a link which read: "Get the facts about mail-in ballots."

Five states in the US already conduct elections primarily by mail-in vote: Utah, Colorado, Hawaii, Washington and Oregon.

For years, Twitter has been accused of ignoring the US President's violation of platform rules with his daily, often hourly barrages of personal insults and inaccurate information sent to more than 80 million followers, news agency AFP reported.

But Twitter's slap on the wrist was enough to drive Mr Trump into a tirade - on Twitter - in which "Republicans feel that Social Media Platforms totally silence conservatives voices. We will strongly regulate, or close them down, before we can ever allow this to happen," Mr Trump said.

He said that an increase in mail-in ballots - seen in some states as vital for allowing people to avoid crowds during the COVID-19 pandemic - will undermine the election.

"It would be a free for all on cheating, forgery and the theft of Ballots," wrote Mr Trump, whose re-election campaign has been knocked off track by the coronavirus crisis. His torrent of angry tweets earned a top-10 trending hashtag: #TrumpMeltdown.

Facebook chief Mark Zuckerberg also waded in to the row, telling Fox News that his social network - still the biggest in the world - has a different policy. "I just believe strongly that Facebook should not be the arbiter of truth of everything that people say online," Mr Zuckerberg said in a snippet of the interview posted online Wednesday by Fox.

"I think, in general, private companies, especially these platform companies, shouldn't be in the position of doing that," he said.

 he claimed that the political right in the US is being censored.

"Republicans feel that Social Media Platforms totally silence conservatives voices. We will strongly regulate, or close them down, before we can ever allow this to happen," Mr Trump said.

He said that an increase in mail-in ballots - seen in some states as vital for allowing people to avoid crowds during the COVID-19 pandemic - will undermine the election.

"It would be a free for all on cheating, forgery and the theft of Ballots," wrote Mr Trump, whose re-election campaign has been knocked off track by the coronavirus crisis. His torrent of angry tweets earned a top-10 trending hashtag: #TrumpMeltdown.

Facebook chief Mark Zuckerberg also waded in to the row, telling Fox News that his social network - still the biggest in the world - has a different policy. "I just believe strongly that Facebook should not be the arbiter of truth of everything that people say online," Mr Zuckerberg said in a snippet of the interview posted online Wednesday by Fox.

"I think, in general, private companies, especially these platform companies, shouldn't be in the position of doing that," he said.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Italian researchers have claimed that they have successfully developed a vaccine to contain coronavirus (COVID-19) which is likely to work on humans, a report said.

Luigi Aurisicchio, CEO of Takis, the firm developing the medication, said that a coronavirus candidate vaccine has neutralised the virus in human cells for the first time, the Arab News reported.

"This is the most advanced stage of testing of a candidate vaccine created in Italy. Human tests are expected after this summer," Aurisicchio was quoted as saying to Italian news agency ANSA.

"According to the Spallanzani Hospital, as far as we know we are the first in the world so far to have demonstrated neutralisation of the coronavirus by a vaccine. We expect this to happen in humans too," he added.

The researchers experimented with the vaccine on mice that had successfully developed antibodies that blocked the virus from infecting the cells. They further observed that the five vaccine candidates generated a large number of antibodies, and selected two with the best results.

All of the vaccine candidates currently being developed are based on the genetic material of DNA protein "spike", the molecular tip used by the coronavirus to enter human cells.

They are injected with the so-called "electroporation" technique, which consists of an intramuscular injection followed by a brief electrical impulse, helping the vaccine break into the cells and activating the immune system, the report said.

Researchers believe that this makes their vaccine particularly effective for generating functional antibodies against the "spike" protein, in particular in the lung cells, which are the most vulnerable to coronavirus.

"We are working hard for a vaccine coming from Italian research, with an all-Italian and innovative technology, tested in Italy and made available to everyone," Aurisicchio was quoted by the Arab News report.

"In order to reach this goal, we need the support of national and international institutions and partners who may help us speed up the process," he noted.

The total number of COVID-19 infections, fatalities and recoveries since the pandemic began has risen to 213,013 in the country.